title: A retrospective analysis of fondaparinux versus enoxaparin treatment in women with infertility or pregnancy loss.
abstract: OBJECTIVE
  We compared the pregnancy success rates and safety parameters of fondaparinux versus enoxaparin, combined with immunotherapy, in patients with a history of miscarriage and/or infertility and coagulant defects.
  
  
  METHODS
  A total of 127 pregnancies in 110 patients with a history of miscarriage and/or infertility were retrospectively evaluated. Of these, 29 pregnancies used fondaparinux 2.5 mg daily and 98 pregnancies used enoxaparin 30 mg twice daily.
  
  
  RESULTS
  The pregnancy success rate was 59% (17/29; 95% CI, 41-75%) for patients receiving fondaparinux and 58% (57/98; 95% CI, 48-68%) for patients receiving enoxaparin. No difference was detected in birth weight (2.7 +/- 0.8 and 2.9 +/- 0.6 kg, respectively) or gestational age at delivery (37.3 +/- 2.2 and 37.7 +/- 2.1 weeks, respectively). No birth defects, severe bleeding-related complications, or serious allergic reactions were observed.
  
  
  CONCLUSIONS
  In patients with a history of miscarriage, infertility, and coagulant defects receiving immunotherapy, fondaparinux resulted in successful pregnancy outcomes comparable with enoxaparin therapy. Although no difference in outcome was observed in our analysis, a much larger study is required to achieve statistical power.
authors.affiliation: Alan E. Beer Center for Reproductive Immunology & Genetics, San Francisco, CA 94111, USA. ewinger@sbcglobal.net
authors.forename: Edward E
authors.initials: EE
authors.lastname: Winger
authors.forename: Jane L
authors.initials: JL
authors.lastname: Reed
mesh_terms: D000022:Abortion, Spontaneous / Q000175:diagnosis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D000328:Adult; D003131:Combined Modality Therapy; D017984:Enoxaparin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D000077425:Fondaparinux; D006801:Humans; D007167:Immunotherapy; D007247:Infertility, Female / Q000175:diagnosis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D011134:Polysaccharides / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D011256:Pregnancy Outcome; D012189:Retrospective Studies
chemical_list: D017984:Enoxaparin; D011134:Polysaccharides; D000077425:Fondaparinux